Literature DB >> 8239578

High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I.

J R Lonks1, A A Medeiros.   

Abstract

Four (5%) of 81 recent isolates of Streptococcus pneumoniae from the blood of adult patients but no isolates from pediatric patients (n = 51) were resistant (MIC, > or = 1 microgram/ml) to erythromycin. The MICs of clarithromycin were slightly lower than those of erythromycin, but there was complete cross-resistance. Routine testing and surveillance are needed to determine whether erythromycin resistance among S. pneumoniae isolates is increasing throughout the United States.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239578      PMCID: PMC188063          DOI: 10.1128/AAC.37.9.1742

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases.

Authors:  G D Fang; M Fine; J Orloff; D Arisumi; V L Yu; W Kapoor; J T Grayston; S P Wang; R Kohler; R R Muder
Journal:  Medicine (Baltimore)       Date:  1990-09       Impact factor: 1.889

2.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989.

Authors:  A Fenoll; C Martín Bourgon; R Muñóz; D Vicioso; J Casal
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

3.  Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group.

Authors:  J S Spika; R R Facklam; B D Plikaytis; M J Oxtoby
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

4.  Resistance to erythromycin in group A streptococci.

Authors:  H Seppälä; A Nissinen; H Järvinen; S Huovinen; T Henriksson; E Herva; S E Holm; M Jahkola; M L Katila; T Klaukka
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

5.  Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary.

Authors:  A Marton; M Gulyas; R Munoz; A Tomasz
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

6.  Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa.

Authors:  M Powell; D McVey; M H Kassim; H Y Chen; J D Williams
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

7.  Antimicrobial susceptibility patterns of Streptococcus pneumoniae.

Authors:  R C Cooksey; R R Facklam; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

8.  Antimicrobial susceptibility testing of pneumococci: determination of Kirby-Bauer breakpoints for penicillin G, erythromycin, clindamycin, tetracycline, chloramphenicol, and rifampin.

Authors:  M R Jacobs; Y Mithal; R M Robins-Browne; M N Gaspar; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.

Authors:  J H Jorgensen; G V Doern; L A Maher; A W Howell; J S Redding
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

10.  Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae.

Authors:  C G Dowson; A Hutchison; N Woodford; A P Johnson; R C George; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

View more
  11 in total

1.  Clarithromycin for children.

Authors:  S M King
Journal:  Can J Infect Dis       Date:  1995-03

2.  Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study.

Authors:  Eric Batard; Marie Emmanuelle Juvin; Cédric Jacqueline; Denis Bugnon; Jocelyne Caillon; Gilles Potel; Henri B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia.

Authors:  Mark I Neuman; Meera Kelley; Marvin B Harper; Thomas M File; Carlos A Camargo
Journal:  J Emerg Med       Date:  2007-03-30       Impact factor: 1.484

4.  Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995.

Authors:  A P Johnson; D C Speller; R C George; M Warner; G Domingue; A Efstratiou
Journal:  BMJ       Date:  1996-06-08

5.  Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.

Authors:  E L Fasola; S Bajaksouzian; P C Appelbaum; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.

Authors:  J F Plouffe; M T Herbert; T M File; I Baird; J N Parsons; J B Kahn; K T Rielly-Gauvin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 7.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 8.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

9.  What Is the Clinical Impact of Macrolide Resistance?

Authors:  John R. Lonks
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 10.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.